Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2025; 17(9): 105896
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.105896
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.105896
Quercetin pretreated umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease via IL-10 /Janus kinase 2/STAT3 signaling
Meng-Yue Shi, Fu-Yuan Yang, Department of Anesthesiology, The First Affiliated Hospital of Yangtze University, Jingzhou 434020, Hubei Province, China
Meng-Yue Shi, School of Medicine, Yangtze University, Jingzhou 434023, Hubei Province, China
Lian Liu, Department of Pharmacology, Medical School of Yangtze University, Jingzhou 434023, Hubei Province, China
Fu-Yuan Yang, Health Science Center, Yangtze University, Jingzhou 434020, Hubei Province, China
Author contributions: Shi MY, Liu L, and Yang FY contributed to the conception and design, collection and/or assembly of the data, data analyses, and interpretation of the manuscript; Shi MY wrote the manuscript; Yang FY approved the final manuscript.
Supported by the Science and Technology Research Project of Hubei Province, No. 2021CFB210; and Central Guiding Local Science and Technology Development Fund Project (Science and Technology Department of Xizang Autonomous Region), No. XZ202401YD0002C.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Health Science Center of Yangtze University, Approval No. CJYXBEC2021-135.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Ethics Committee of Health Science Center of Yangtze University (Approval No. CJYXBEC2021-135).
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Yuan Yang, PhD, Department of Anesthesiology, The First Affiliated Hospital of Yangtze University, No. 55 Jianghan North Road, Shashi District, Jingzhou 434020, Hubei Province, China. ivansblue@sina.com
Received: February 10, 2025
Revised: April 7, 2025
Accepted: August 4, 2025
Published online: September 26, 2025
Processing time: 226 Days and 19.6 Hours
Revised: April 7, 2025
Accepted: August 4, 2025
Published online: September 26, 2025
Processing time: 226 Days and 19.6 Hours
Core Tip
Core Tip: Quercetin (QUR) pretreatment enhanced the viability of human umbilical cord-derived mesenchymal stem cells (hUCMSCs), which may improve their immune regulatory ability. Intraperitoneal injection of QUR-hUCMSCs effectively alleviated inflammation in 2,4,6-trinitrobenzenesulfonic acid mice, and the therapeutic effect was superior to untreated hUCMSCs. QUR-hUCMSC treatment significantly enhanced interleukin 10 (IL-10) expression in 2,4,6-trinitrobenzenesulfonic acid mice. QUR-hUCMSCs inhibited inflammatory bowel disease inflammation by regulating the IL-10/Janus kinase/signal transducer and activator of transcription signaling pathway.